Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Total Current Liabilities data on file, last reported at $73.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 20.9% year-over-year to $73.4 million; the trailing twelve-month figure through Dec 2025 stood at $73.4 million (up 20.9% YoY), and the FY2025 full-year result was $73.4 million, up 20.9% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $73.4 million, down from $83.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $83.1 million in Q3 2025 and bottomed at $28.2 million in Q2 2021.
• The 5-year median for Total Current Liabilities is $41.0 million (2023), against an average of $46.2 million.
• The widest annual swing landed in 2021, when Total Current Liabilities declined 15.11%; it then soared 66.61% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $28.6 million in 2021, then soared by 62.4% to $46.4 million in 2022, then slipped by 3.51% to $44.7 million in 2023, then soared by 35.78% to $60.7 million in 2024, then gained by 20.9% to $73.4 million in 2025.
• The last three Total Current Liabilities figures came in at $73.4 million (Q4 2025), $83.1 million (Q3 2025), and $68.2 million (Q2 2025), per Business Quant data.

Peer Comparison